Spirapril

Spirapril
IUPAC ime
	(8S)-7-[(2S)-2- {[(2S)-1-etoksi-1-okso-4-fenilbutan-2-il]amino}propanoil]-1,4-ditia-7-azaspiro[4.4]nonan-8-karboksilna kiselina
Klinički podaci
Drugs.com	Internacionalno ime leka
Kategorija trudnoće	D;
Način primene	Oralno
Pravni status
Pravni status	℞ (Prescription only);
Farmakokinetički podaci
Bioraspoloživost	50%
Metabolizam	konvertuje se u spiraprilat
Poluvreme eliminacije	30 do 35 sati
Izlučivanje	Hepatički i renalno
Identifikatori
CAS broj	83647-97-6
ATC kod	C09AA11 (WHO)
PubChem	CID 5311447
DrugBank	DB01348
ChemSpider	4470933
UNII	96U2K78I3V
KEGG	D08529
ChEMBL	CHEMBL431
Hemijski podaci
Formula	C22H30N2O5S2
Molarna masa	466,616 g/mol
	SMILES O=C(OCC)[C@@H](N[C@H](C(=O)N2[C@H](C(=O)O)CC1(SCCS1)C2)C)CCc3ccccc3; ;
	InChI InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1 ; Key:HRWCVUIFMSZDJS-SZMVWBNQSA-N ;

Spirapril hidrohlorid (Renormax) je ACE inhibitor antihipertenzivni lek koji se koristi u tretmanu hipertenzije. On pripada dikarboksilnoj grupi ACE inhibitora.

Poput mnogih ACE inhibitora, ovaj lek je prolek koji se konvertuje do aktivnog metabolita spiraprilata nakon oralne administracije. Za razliku od drugih članova grupe, on se eliminiše renalnim i hepatičkim putem, te je podesniji za primenu kod pacijenata sa renalnim oštećenjima.^[1]^[2]

Osobine[уреди | уреди извор]

Osobina	Vrednost
Broj akceptora vodonika	8
Broj donora vodonika	2
Broj rotacionih veza	10
Particioni koeficijent^[3] (ALogP)	0,3
Rastvorljivost^[4] (logS, log(mol/L))	-5,4
Polarna površina^[5] (PSA, Å²)	146,5

Reference[уреди | уреди извор]

^ Shohat J, Wittenberg C, Erman A, Rosenfeld J, Boner G (1999). „Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension.”. Scand J Urol Nephrol. 33 (1): 57—62. PMID 10100366. doi:10.1080/003655999750016294.
^ Noble S, Sorkin E (1995). „Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.”. Drugs. 49 (5): 750—66. PMID 7601014.
^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t. уреди
^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e. уреди

Literatura[уреди | уреди извор]

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze[уреди | уреди извор]

Spirapril

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Shohat J, Wittenberg C, Erman A, Rosenfeld J, Boner G (1999). „Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension.”. Scand J Urol Nephrol. 33 (1): 57—62. PMID 10100366. doi:10.1080/003655999750016294.

[2] Noble S, Sorkin E (1995). „Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.”. Drugs. 49 (5): 750—66. PMID 7601014.

[3] Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.

[4] Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t. уреди

[5] Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e. уреди

[1]

[2]

[3]

[4]

[5]